Compare MXCT & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | NRO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 186.3M |
| IPO Year | 2021 | 2003 |
| Metric | MXCT | NRO |
|---|---|---|
| Price | $1.56 | $2.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 205.0K |
| Earning Date | 11-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $2.48 |
| 52 Week High | $1.81 | $3.21 |
| Indicator | MXCT | NRO |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 54.23 |
| Support Level | $1.17 | $2.49 |
| Resistance Level | N/A | $3.07 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 75.12 | 87.50 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").